2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma.
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma (RCC).
Interfering in the IDO pathway can result in a tumor microenvironment that allows for a more enhanced immune response, says Hammers.
Early data out of ASCO 2017 showed an improved response rate with the combination of an IDO inhibitor and a PD-1 inhibitor, resulting in a phase III trial comparing that combination to sunitinib (Sutent) in RCC.